AIOM· @AIOMtweet · X·· 1 day agoScore70
Body · original
#ESMO26: i risultati dello studio VOLGA aprono nuove prospettive nella cura del #tumoredellavescica muscolo-invasivo.
Leggi l'articolo: https://www.medinews.it/comunicati/tumore-della-vescica-muscolo-invasivo-durvalumab-perioperatorio-piu-enfortumab-vedotin-neoadiuvante-ha-ridotto-il-rischio-di-recidiva-del-49-e-il-rischio-di-morte-del-42/
@myESMO
27 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: AIOM · x.com
